Moderna-Merck mRNA vaccine cuts melanoma recurrence risk in Phase 3

Moderna and Merck announced on Wednesday, August 19, 2026, that a large-scale Phase 3 clinical trial of their personalized mRNA cancer vaccine successfully met its primary goals, significantly reducing the risk of melanoma recurrence and spreading in high-risk patients.